October 2016October 2016
New Product - Varilrix HSA-free
Varilrix HSA-free (varicella vaccine, live attenuated (human albumin free)) is a lyophilised preparation of the live attenuated Oka strain of varicella zoster virus, obtained by propagation of the virus in MRC5 human diploid cell culture. Varilrix is indicated for active immunisation against varicella of healthy subjects from 9 months of age. Groups who would particularly benefit from vaccination include: nonimmune adults, especially those in at risk occupations such as health care workers, teachers and workers in children’s day care centres; nonimmune parents of young children; and nonimmune household contacts, both adults and children, of immunocompromised patients with no history of the disease. Varilrix is contraindicated in the following: subjects with known hypersensitivity to neomycin (history of contact dermatitis to neomycin is not a contraindication); pregnancy (pregnancy should be avoided for three months after vaccination); in individuals with primary and acquired immunodeficiency states, including those who are immunosuppressed in association with AIDS or other clinical manifestations of infections with human immunodeficiency virus; cellular immune deficiencies; hypogammaglobulinemic and dysgammaglobulinemic states; leukaemias, lymphomas and blood dyscrasias. Varilrix is also contraindicated with a family history of congenital or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated. As with other vaccines, the administration of Varilrix should be postponed in subjects suffering from acute severe febrile illness. Varilrix is available as a powder for injection in a vial with 0.5 mL of sterile water diluent included in packs of 1’s and 10’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au